Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma

NCT01761266 is registered in ClinicalTrials.gov with Eisai Limited as lead sponsor.

NCT NCT01761266
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01761266 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma
Lead sponsor
Eisai Limited
Phase
Phase 3
Overall status
Completed
Start date
March 1, 2013
Completion date
March 10, 2021
Enrollment
954 (actual)
Sites
186

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc)